Clinical trials: Bronchial Neoplasms
Solid Tumors, ER+ Breast Cancer
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.
- Conditions
- Solid Tumors, ER+ Breast Cancer, Triple Negative Breast Cancer, TNBC, ARID1A Gene Mutation
- Trial name
- NCT05490472
- Testing
- JAB-2485 (Aurora A inhibitor)
- Where
- 8 sites in United States, China
- Volunteers
- 102 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Non-Small Cell Lung Cancer
Precision Medicine Randomized Clinical Trial Comparing Molecular Tumor Board Assisted Care to Usual Care
This trial will compare Molecular Tumor Board (MTB) assisted care to usual care for patients who have newly diagnosed histologically or cytologically confirmed stage IIb-IV Non-Small Cell Lung Cancer (NSCLC) and are planning to…
- Trial name
- PRiMAL (NCT05254795)
- Testing
- Molecular tumor board assisted care
- Where
- United States
- Volunteers
- 659 people
- Sponsor
- Timothy Mullett
Carcinoma, Non-Small-Cell Lung
Study of Salirasib to Treat Non-Small Cell Lung Cancer
The purpose of this study is to determine whether Salirasib is effective to shrink or prevent the growth of the tumors associated with non-small cell lung cancer in both patients who are newly diagnosed or have recurrent disease.
- Trial name
- NCT00531401
- Testing
- Salirasib
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Concordia Pharmaceuticals, Inc
Patients With Suspected Non-small Cell Lung Cancer (NSCLC) at Clinical Stage T1
Anesthesia Comparison in Early-stage Small NSCLC: A Multicenter RCT
This study is a prospective, randomized, controlled study, which intends to enroll patients with suspected early-stage NSCLC (non-small cell lung cancer) with a diameter of ≤ 3 cm as research subjects.
- Trial name
- NCT07327736
- Testing
- Non-intubated video-assisted thoracic surgery with spontaneous breathing (NIVATS)
- Volunteers
- 410 people
- Sponsor
- Tang-Du Hospital
Non-Small Cell Lung Cancer
SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer
Efficacy and Safety of SYHX2011 Combined with Carboplatin and Enlonstobart versus Nab-Paclitaxel Combined with Carboplatin and Tislelizumab as First-Line Treatment for Squamous Non-Small Cell Lung Cancer
- Trial name
- NCT07662811
- Testing
- SYHX2011, Carboplatin, Enlonstobart
- Volunteers
- 396 people
- Sponsor
- Shanghai Chest Hospital
Non-small Cell Lung Cancer
Pemetrexed With or Without Carboplatin for Elderly Non-squamous Non-small Cell Lung Cancer
The number of NSCLC patients above 70 years of age who are non-squamous histology is increasing around the world. Although previous guidelines often recommend single agent therapy for NSCLC, recent studies suggest that platinum…
- Trial name
- ACE (NCT01593293)
- Testing
- PemCarbo, Pem only
- Where
- South Korea
- Volunteers
- 266 people
- Sponsor
- Asan Medical Center
Lung Cancer, Extensive-stage Small-cell Lung Cancer
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
The purpose of this study was to evaluate the safety and efficacy of low-dose radiotherapy (LDRT) combined with sugemalimab, olaparib, chemotherapy in the first-line treatment of SLFN-11 positive extensive stage small cell lung…
- Trial name
- NCT06217757
- Testing
- Low-dose radiotherapy, Etoposide, Cisplatin
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Sichuan University
Pleural Effusions, Chronic, Pleural Effusion, Malignant
Respiratory Function of Dexmedetomidine in Patients Undergoing Pleuroscopy
The primary objective of this prospective trial will be to assess the effects of dexmedetomidine administration on oxygenation and respiratory function in patients undergoing diagnostic or therapeutic medical…
- Conditions
- Pleural Effusions, Chronic, Pleural Effusion, Malignant, Pleural Diseases
- Trial name
- NCT03597828
- Where
- Greece
- Volunteers
- 60 people
- Sponsor
- Attikon Hospital
Breast Cancer, Non-Small Cell Lung Cancer
131-I-TM-601 Study in Adults With Solid Tumors
This study is designed to evaluate the ability of intravenously (IV)administered 131-I-labeled TM-601 (chlorotoxin) to provide tumor-specific localization(via radiographic imaging) in patients with recurrent or refractory primary…
- Conditions
- Breast Cancer, Non-Small Cell Lung Cancer, Melanoma, Colorectal Cancer
- Trial name
- NCT00379132
- Testing
- 131-I-TM-601 (chlorotoxin)
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- TransMolecular
Non-small Cell Lung Cancer
Iressa/Docetaxel in Non-Small-Cell Lung Cancer
Patients will receive 250 mg Iressa by mouth daily each day while on this study. Patients will also receive docetaxel 30 mg/m2 by by vein (IV) on day 1 weekly for the first 3 weeks of each course of therapy.
- Trial name
- NCT00048087
- Testing
- ZD1839, Docetaxel
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib
This randomized phase II trial studies how well pemetrexed disodium and carboplatin or cisplatin with or without erlotinib hydrochloride work in treating patients with epidermal growth factor receptor (EGFR) mutant positive stage…
- Trial name
- NCT01928160
- Testing
- pemetrexed disodium, carboplatin, cisplatin
- Sponsor
- Vanderbilt-Ingram Cancer Center
Non Small Cell Lung Cancer (NSCLC), Melanoma (Skin Cancer)
Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis
The NeutroFlow study is a multi-center clinical trial designed to develop a computational model that converts flow cytometry results into a prediction of clinical benefit.
- Conditions
- Non Small Cell Lung Cancer (NSCLC), Melanoma (Skin Cancer), Triple Negative Breast Cancer (TNBC), RCC, Renal Cell Cancer
- Trial name
- NEUTROFLOW (NCT07246759)
- Testing
- Blood sample collection
- Where
- 3 sites in Germany, Italy and 1 more
- Volunteers
- 600 people
- Sponsor
- OncoHost Ltd.
Non-Small-Cell Lung Cancer
Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer
Open-label multicenter randomized Phase III trial.
- Trial name
- NATCH (NCT00913705)
- Testing
- Neoadjuvant chemotherapy (taxol and carboplatin), Adjuvant chemotherapy (taxol and carboplatin), Surgery
- Volunteers
- 624 people
- Sponsor
- Spanish Lung Cancer Group
Non Small Cell Lung Cancer
Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer
Although several clinical trials provide evidence for efficacy benefit for Checkpoint Inhibitors plus chemotherapy for lung cancer. However, there was rare evidence for clinical evidence in Hunan province.
- Trial name
- CREATE (NCT05059951)
- Testing
- Immune checkpoint inhibitor
- Where
- China
- Volunteers
- 15,000 people
- Sponsor
- Hunan Province Tumor Hospital
Dyspnea, Lung Cancer
Losartan in Treating Pulmonary Fibrosis in Patients With Stage I, II, or III Non-Small Cell Lung Cancer
RATIONALE: Losartan potassium may be effective in treating pulmonary fibrosis caused by radiation therapy in patients with non-small cell lung cancer.
- Conditions
- Dyspnea, Lung Cancer, Pulmonary Complications, Radiation Fibrosis
- Trial name
- NCT00880386
- Testing
- Losartan
- Sponsor
- University of South Florida
Non-Small Cell Lung Cancer
A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer
The purpose of this study is to determine the safety and efficacy of BMS-986207 in combination with nivolumab and ipilimumab as first-line treatment for participants with stage IV non-small cell lung cancer (NSCLC).
- Trial name
- NCT05005273
- Testing
- Nivolumab, Ipilimumab, BMS-986207
- Where
- 71 sites in United States, Argentina and 10 more
- Volunteers
- 1 people
- Sponsor
- Bristol-Myers Squibb
Non-small-cell Lung Cancer, Adenocarcinoma
TS Gene Polymorphism Predicts Effect in Patients With Advanced Lung Cancer
The investigators performed a multicenter, open trial of using TS gene polymorphism to predict advanced lung adenocarcinoma effect to pemetrexed combined with cisplatin regiment as first-line treatment.
- Trial name
- TPEIAL (NCT00940069)
- Testing
- pemetrexed
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hunan Province Tumor Hospital
Non-small Cell Lung Cancer
Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
The purpose of this study is to understand if treatment with one chemotherapy medication combined with immune therapy (pembrolizumab) is tolerable and effective for patients with lung cancer and performance status of 2 (PS2)…
- Trial name
- NCT04297605
- Testing
- Pembrolizumab, Pemetrexed (Chemotherapy), Nab-paclitaxel (Chemotherapy)
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Rochester
Breast Cancer (Triple Negative Breast Cancer (TNBC)), Renal Cell Carcinoma (Kidney Cancer)
Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment and work by blocking protein interactions that normally prevent the immune system from recognizing and destroying cancer cells.
- Conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC)), Renal Cell Carcinoma (Kidney Cancer), Melanoma (Skin Cancer), Non-Small Cell Lung Cancer
- Trial name
- NCT07555210
- Testing
- Dual-Energy X-ray Absorptiometry (DXA), High Resolution peripheral Quantitative Computed Tomography (HRpQCT)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Jessica Mezzanotte Sharpe
Non-Small Cell Lung Cancer, Urothelial Cancer
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
This is a Phase 2 study to evaluate the safety and efficacy of avelumab in combination with axitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior platinum…
- Trial name
- NCT03472560
- Testing
- Avelumab (MSB0010718C), Axitinib (AG-013736)
- Where
- 39 sites in United States, Hungary and 6 more
- Volunteers
- 61 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.